Previous 10 | Next 10 |
Biostage ( OTC:BSTG ): Q2 GAAP EPS of -$0.37. More news on: Biostage, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOLLISTON, Mass. , Aug. 13, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial re...
HOLLISTON, Mass. , Aug. 7, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the...
Biostage, Inc. (BSTG) Q1 2019 Earnings Conference Call May 14, 2019 09:00 AM ET Company Participants Tom McNaughton - Chief Financial Officer Jim McGorry - Chief Executive Officer Bill Fodor - Chief Scientific Officer Conference Call Participants John Ajay - Ajay Capital M...
HOLLISTON, Mass. , May 14, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financia...
HOLLISTON, Mass. , May 8, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the ...
Biostage Inc (BSTG) Q4 2018 Results Earnings Conference Call March 28, 2019 9:00 AM ET Company Participants Tom McNaughton - Chief Financial Officer Jim McGorry - Chief Executive Officer Conference Call Participants John Ajay - Ajay Capital Presentation Operator ...
Biostage ( OTC:BSTG ): Q4 GAAP EPS of -$0.32. More news on: Biostage, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HOLLISTON, Mass. , March 28, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financ...
HOLLISTON, Mass. , March 21, 2019 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will report its financial results for the qu...
News, Short Squeeze, Breakout and More Instantly...
Entered into securities purchase agreements with accredited investors for a $1.5 million private investment in public equity (PIPE) financing. The transaction closed on April 15, 2024. Received $0.5 million in convertible debt from Company’s CEO in February 2024. Hollisto...
Established a Research Collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to Study the Repair and Regeneration of the Colon following Colectomy Established a Collaboration with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproduct...
Holliston, MA, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate o...